9 Meters Biopharma, Inc. (NMTRQ)

Market Cap	14.00 -90.3%
Revenue (ttm)	n/a
Net Income	-46.28M
EPS	-3.53
Shares Out	14.46M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,001
Open	0.000001
Previous Close	n/a
Day's Range	0.000001 - 0.000001
52-Week Range	n/a
Beta	8.28
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About 9 Meters Biopharma

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to preven...

• Industry: Biotechnology
• Sector: Healthcare
• Employees: 10
• Stock Exchange: OTCMKTS
• Ticker Symbol: NMTRQ

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 21, 2026

Data Sources Report a data error